---
title: Incorporation of immunotherapy into frontline treatment for adults with B-cell
  precursor acute lymphoblastic leukemia
date: '2024-09-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39236292/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240906182413&v=2.18.0.post9+e462414
source: Blood
description: Although complete remission rates in adults with B-cell precursor acute
  lymphoblastic leukemia (BCP-ALL) have improved over the last two decades, it is
  still inferior to that of the pediatric population and once in remission, the risk
  of relapse is still high. Furthermore, while pediatric-inspired chemotherapy regimens
  have improved long-term outcomes for adolescents and young adults, these intensive
  chemotherapy regimens are not well tolerated in older patients and are associated
  with ...
disable_comments: true
---
Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last two decades, it is still inferior to that of the pediatric population and once in remission, the risk of relapse is still high. Furthermore, while pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with ...